This document discusses methods of assessing and treating pain in children. It begins by outlining three ways to assess pain in children: asking the child directly using a pain scale, asking parents or caregivers, and observing the child's behavior. It then provides more details on the Wong-Baker FACES scale and FLACC scale for assessing pain levels in older and younger children respectively. The document reviews the WHO analgesic ladder for treating pain in children, which is a two-step approach using non-opioids for mild pain and strong opioids like morphine for moderate to severe pain. It provides dosing guidelines for common pain medications in children of different ages. The principles of managing procedural pain and side effects of opioids are also summarized.
“Clinicians should proactively talk to their patients of reproductive age about ECPs and offer advance prescriptions for ECPs during routine gynecologic office visits….”
“Clinicians should proactively talk to their patients of reproductive age about ECPs and offer advance prescriptions for ECPs during routine gynecologic office visits….”
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
Acute scrotum is a general term referring to an emergency condition affecting the contents or the wall of the scrotum.
There are a number of conditions that present acutely, predominantly with pain and/or swelling
A careful and detailed history and examination, and in some cases, investigations allow differentiation between these diagnoses. A prompt diagnosis is essential as the patient may require urgent surgical intervention
Testicular torsion refers to twisting of the spermatic cord, causing ischaemia of the testicle.
Testicular torsion results from inadequate fixation of the testis to the tunica vaginalis producing ischemia from reduced arterial inflow and venous outflow obstruction.
The prevalence of testicular torsion in adult patients hospitalized with acute scrotal pain is approximately 25 to 50 percent
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
1. Treatment in children
Disclaimer: This presentation contains information on the general principles of pain management. This presentation cannot account for
individual variation among patients and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It
is the responsibility of the treating physician, or health care provider, to determine the best course of treatment for the patient. Treat the
Pain and its partners assume no responsibility for any injury or damage to persons or property arising out of or related to any use of
these materials, or for any errors or omissions. Last updated on January 12, 2015
2. Objectives
• Review methods of assessing pain in children
• Discuss treatment options and dosing for children based on
the age of the child and their level of pain
2
3. Three ways to assess pain in children
• Ask the child: FACES scale
• Ask the parent or caregiver
– Ask about previous exposure to pain, verbal pain
indicators, usual behavior or temperament
• Observe the child: FLACC scale
• The child is the best person to report their pain
Children’s Palliative Care in Africa, 2009 3
4. Wong-Baker FACES scale
• Use in children who can talk (usually 3 years and older)
• Explain to the child that each face is for a person who feels
happy because he has no pain, or a little sad because he has a
little pain, or very sad because he has a lot of pain
• Ask the child to pick one face that best describes his or her
current pain intensity
• Record the number of the pain level that the child reports to
make treatment decisions, follow-up, and compare between
examinations
Palliative Care for HIV/AIDS and Cancer Patients in Vietnam, Basic Training Curriculum: Harvard Medical School, Centre for
Palliative Care (2007) 4
5. FLACC scale
ICPCN (2009): Adapted from Merkel et al 5
• Use in children less than 3 years of age or older children who can’t talk
• Use it like an APGAR (Appearance, Pulse, Grimace, Activity, Respiration) score,
arriving at a score out of 10
6. Practice using FLACC scale
• Samuel is 18 months old. You observe that he is withdrawn,
kicking his legs, and squirming. His is constantly crying or
screaming, but is calmed down by breastfeeding.
6
Category Score
Face
Legs
Activity
Cry
Consolability
Total
Score
1
Score
1
2
Score
1
2
1
Score
1
2
1
2
Score
1
2
1
2
1
Score
1
2
1
2
1
7
7. Practice using FLACC scale
• Samuel is 18 months old. You observe that he is withdrawn,
kicking his legs, and squirming. His is constantly crying or
screaming, but is calmed down by breastfeeding.
7
Category Score
Face
Legs
Activity
Cry
Consolability
Total
Score
1
Score
1
2
Score
1
2
1
Score
1
2
1
2
Score
1
2
1
2
1
Score
1
2
1
2
1
7
8. 8
Mild pain
Moderate or
Severe pain
Step 1
Non-opioid
Step 2
Strong opioid
+/- adjuvant
+/- non-opioid
+/- adjuvant
Consider prophylactic laxatives
to avoid constipation
Step up if
pain persists
or increases
Non-opioids Age>3 mos: ibuprofen or paracetamol (acetaminophen); Age<3 mos: paracetamol
Strong opioids morphine (medicine of choice) or fentanyl, oxycodone, hydromorphone, buprenorphine
Adjuvants antidepressant, anticonvulsant, antispasmodic, muscle relaxant, bisphosphonate, or
corticosteroid
Combining an opioid and non-opioid is effective, but do not combine drugs of the same class.
Time doses based on drug half-life (“dose by the clock”); do not wait for pain to recur
Ref: Adapted by Treat the Pain from World Health Organization http://www.who.int/cancer/palliative/painladder/en/ (accessed 7 November 2013)
WHO Analgesic Ladder: Pediatric
8
9. WHO ladder: pediatric
• Recently updated guidelines from the World Health
Organization (WHO) recommend using a 2-step ladder which
does not include the rung for weak opioids
• Weak opioids are not recommended for use in children
– Codeine
• Safety and efficacy problems related to genetic
variability that affects metabolism
• Low analgesic effect in infants and young children
– Tramadol
• Data are lacking on safety and efficacy in children
WHO guidelines on the pharmacological treatment of persisting pain in children with medical illnesses, WHO (2012) 9
10. Step 1: mild pain
• Paracetamol and ibuprofen are the only medicines in this step
– No other NSAIDs are recommended
• Infants <3 months old
– Only paracetamol is recommended
• Children >3 months old
– Paracetamol or ibuprofen can be used
WHO guidelines on the pharmacological treatment of persisting pain in children with medical illnesses, WHO (2012) 10
11. Dosing of Step 1 analgesics
WHO guidelines on the pharmacological treatment of persisting pain in children with medical illnesses, WHO (2012) 11
Medicine <1 month 1-3 months 3 months-12
years
Maximum daily
dose
Paracetamol 5-10mg/kg every
6-8 hours
10mg/kg every 4-
6 hours
10-15mg/kg every
4-6 hours (max 1g
at a time)
4 doses per day
Ibuprofen Not recommended 5-10mg/kg every
6-8 hours
40mg/kg/day
* Children with poor nutritional state may be more susceptible to toxicity at standard doses
12. Step 2: moderate or severe pain
“There is no other class of medicines than strong opioids that is
effective in the treatment of moderate and severe pain.
Therefore, strong opioids are an essential element in pain
management.”
World Health Organization
WHO guidelines on the pharmacological treatment of persisting pain in children with medical illnesses, WHO (2012) 12
13. Step 2: moderate or severe pain
• Morphine is the “medicine of choice”
– Alternatives can be used if a child experiences intolerable
side-effects
• As with adults, there is no maximum dose for opioids
– Titrate upward to find the dose that relieves pain with
tolerable side-effects
• Constipation is a common side effect, and all children taking
opioids should also take a stimulant laxative and a stool
softener
WHO guidelines on the pharmacological treatment of persisting pain in children with medical illnesses, WHO (2012) 13
14. Starting dose for opioid-naïve neonates
WHO guidelines on the pharmacological treatment of persisting pain in children with medical illnesses, WHO (2012) 14
Medicine Route Starting dose
Morphine IV/Sc injection 25-50mcg/kg every 6 hours
IV infusion Initial IV dose 25-50mcg/kg, then 5-10mcg/kg/hour
100mcg/kg every 4 or 6 hours
Fentanyl IV injection 1-2mcg/kg every 2 to 4 hours
IV infusion Initial IV dose 1-2mcg/kg, then 0.5-1mcg/kg/hour
* Administer IV morphine slowly over at least 5 minutes
* IV doses are based on acute pain management and sedation. Lower doses are required for non-ventilated
neonates
* Administer IV fentanyl slowly over 3-5 minutes
15. Starting dose for opioid-naïve infants (1 mo-1 yr)
WHO guidelines on the pharmacological treatment of persisting pain in children with medical illnesses, WHO (2012) 15
Medicine Route Starting dose
Morphine Oral (immediate release) 80-200mcg/kg every 4 hours
IV/Sc injection 1-6 months: 100mcg/kg every 6 hours
6-12 months: 100mcg/kg every 4 hours
(max 2.5mg/dose)
IV infusion 1-6 months: Initial IV dose: 50mcg/kg, then:
10-30mcg/kg/hour
6-12 months: Initial IV dose: 100-200mcg/kg
then: 20-30mcg/kg/hour
Sc infusion 1-3 months: 10mcg/kg/hour
3-12 months: 20mcg/kg/hour
* Administer IV morphine slowly over at least 5 minutes
16. Starting dose for opioid-naïve infants (1 mo-1 yr)
WHO guidelines on the pharmacological treatment of persisting pain in children with medical illnesses, WHO (2012) 16
Medicine Route Starting dose
Fentanyl IV injection 1-2mcg/kg every 2 to 4 hours
IV infusion Initial IV dose 1-2mcg/kg, then 0.5-
1mcg/kg/hour
Oxycodone Oral (immediate release) 50-125mcg/kg every 4 hours
* IV doses of fentanyl are based on acute pain management and sedation dosing information
17. Starting doses for opioid-naïve children (1-12 yrs)
WHO guidelines on the pharmacological treatment of persisting pain in children with medical illnesses, WHO (2012) 17
Medicine Route Starting dose
Morphine Oral (immediate release) 1-2 years: 200-400mcg/kg every 4
hours
2-12 years: 200-500mcg/kg every 4
hours (max 5mg)
Oral (prolonged release) 200-800 mcg/kg every 12 hours
IV/Sc injection 1-2 years: 100mcg/kg every 4 hours
2-12 years: 100-200mcg/kg every 4
hours (max 2.5mg)
IV infusion Initial IV dose: 100-200mcg/kg, then
20-30 mcg/kg/hour
Sc infusion 20mcg/kg/hour
* Administer IV morphine slowly over at least 5 minutes
18. Starting doses for opioid-naïve children (1-12 yrs)
WHO guidelines on the pharmacological treatment of persisting pain in children with medical illnesses, WHO (2012) 18
Medicine Route Starting dose
Fentanyl IV injection 1-2mcg/kg, repeated every 30-60 minutes
IV infusion Initial IV dose 1-2mcg/kg, then 1mcg/kg/hour
Hydromorphone Oral (immediate release) 30-80mcg/kg/hour every 3 to 4 hours (max 2mg/dose)
IV/Sc injection 15mcg/kg every 3 to 6 hours
Methadone Oral (immediate release) 100-200mcg/kg every 4 hours for the first 2-3 doses, then
every 6 to 12 hours (max 5mg/dose initially)
IV/Sc injection
Oxycodone Oral (immediate release) 125-200 mcg/kg every 4 hours (max 5mg/dose)
Oral (slow release) 5mg every 12 hours
* Administer IV fentanyl slowly over 3-5 minutes
* Hydromorphone is a potent opioid and significant differences exist between oral and intravenous dosing. Use extreme
caution when converting from one route to another. In converting from parenteral to oral hydromorphone, doses may
need to be titrated up to 5 times the IV dose. Administer IV hydromorphone slowly over 2-3 minutes
* Due to the complex nature and wide inter-individual variation in pharmacokinetics, methadone should only be
commenced by experienced practitioners
These opioids are more complex and should be started by an experienced provider
19. General principles
• Dose at regular intervals
– Medicines should always be given on a regular schedule and not
“as needed”, except for rescue doses
• Use the appropriate route of administration
– Medicines should be given by the simplest, most effective, and
least painful route
• Oral is preferred
• IV or subcutaneous, rectal, or transdermal are alternatives
when oral is not feasible
• IM is discouraged because it is painful
• Adapt treatment to the individual child
– Titrate to get to the correct dose
WHO guidelines on the pharmacological treatment of persisting pain in children with medical illnesses, WHO (2012) 19
20. Side effects of opioids
Opioids are generally well-tolerated
• Mild sedation for first 48 hours is normal while child catches
up on sleep
• Constipation: treat with laxatives
• Pruritis: treat with topical treatments (calamine or
hydrocortizone) or oral antihistamines
• Urinary retention: treat with carbachol or bethanechol;
catheterization may be required
Children’s Palliative Care in Africa, Amery (2009) 20
21. Co-analgesia in children
• The WHO does not recommend corticosteroids or
biphosphonates to treat pain in children
• Neuropathic pain in children
– Consult an expert
– WHO guidance in this area is limited due to lack of
evidence
WHO guidelines on the pharmacological treatment of persisting pain in children with medical illnesses. WHO (2012) 21
22. Procedural pain management principles
• Avoid non-necessary procedures
• Prepare for the procedure
• Involve the child and family
• Encourage the parents to be helpful and supportive
• Carry out procedures in child-friendly area away from the bed
• Use non-pharmacological and pharmacological interventions
to manage pain and anxiety
• After completing the procedure, congratulate the child and
instill a sense of achievement
Children’s Palliative Care in Africa, Amery (2009) 22
23. Procedural pain management
Drugs to use
• Topical anaesthetic agents (EMLA cream)
• Local anaesthetic: S/c lidocaine (make sure it is at body
temperature and buffer with sodium bicarbonate to reduce
pain of administration)
• If anxiety, rather than pain, is the issue: sedate with
benzodiazepine, pedichloryal (50-100mg/kg by mouth) or
promethizine (5mg/kg by mouth)
• If pain is the issue: use opioids in treatment doses
Children’s Palliative Care in Africa, Amery (2009) 23
24. Take home messages
• Pain in children can be assessed using observation and easy
tools
• Children as young as 3 years old can indicate their severity of
the pain
• For children, the WHO analgesic ladder is 2 steps
24
25. References
• African Palliative Care Association. Beating Pain: a pocketguide for pain management in Africa, 2nd
Ed. [Internet]. 2012. Available from:
http://www.africanpalliativecare.org/images/stories/pdf/beating_pain.pdf
• African Palliative Care Association. Using opioids to manage pain: a pocket guide for health
professionals in Africa [Internet]. 2010. Available from:
http://www.africanpalliativecare.org/images/stories/pdf/using_opiods.pdf
• Amery J, editor. Children’s Palliative Care in Africa [Internet]. 2009. Available from:
http://www.icpcn.org/wp-content/uploads/2013/08/Childrens-Palliative-Care-in-Africa-Full-
Text.pdf
• Kopf A, Patel N, editors. Guide to Pain Management in Low-Resource Settings [Internet]. 2010.
Available from: http://www.iasp-
pain.org/files/Content/ContentFolders/Publications2/FreeBooks/Guide_to_Pain_Management_in_
Low-Resource_Settings.pdf
• The Palliative Care Association of Uganda and the Uganda Ministry of Health. Introductory Palliative
Care Course for Healthcare Professionals. 2013.
• World Health Organization. WHO guidelines on the pharmacological treatment of persisting pain in
children with medical illnesses [Internet]. 2012. Available from:
http://www.who.int/medicines/areas/quality_safety/guide_perspainchild/en/
25